Dow Inc. — Cyborg Score 5/10

Strategic Profile

Dow expects $500M in value from its restructuring program during 2026, with two-thirds coming from productivity gains. The company is executing a $1B cost-cutting plan ahead of schedule, with emphasis on simplifying operations and resetting cost structure.

Cyborg Score Rationale

Despite recent losses, analysts are cautiously optimistic about potential long-term recovery and undervaluation opportunities. The company faces cyclical chemical market headwinds but is aggressively executing cost initiatives.

Top Insights

• Net sales declined 9% year-over-year to $9.5 billion in Q4 2025, reflecting declines across all operating segments
• Market cap of $23.32B with 6.5% dividend yield offers attractive income for dividend-focused investors
• Stock surged 40% year-to-date amid restructuring execution, suggesting market belief in recovery potential
• Company employs approximately 34,600 people as of February 2026

Named Competitors

• DuPont — Diversified specialty chemicals and materials
• LyondellBasell — Petrochemicals and refining
• Huntsman — Chemical manufacturing and production
• Celanese — Advanced engineered materials

Recent Developments

• (January 2026) Launched "Transform to Outperform" restructuring program targeting $2B operational EBITDA improvement
• (January 2026) Announced 4,500 job cuts and Q4 2025 net loss of $1.543 billion
• (February 2026) Stock reached 40% year-to-date gains with 6.5% dividend yield amid recovery optimism

Open the full interactive Dow Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.